ARTICLE | Clinical News
Elamipretide ophthalmic solution 1%: Phase II started
June 20, 2016 7:00 AM UTC
Stealth began the double-blind, placebo-controlled, U.S. Phase II ReSIGHT trial to evaluate twice-daily topical elamipretide eye drops for 12 weeks in about 12 patients. Patients will receive elamipre...